China Biologic Products (NASDAQ:CBPO) was upgraded by analysts at BidaskClub from a “strong sell” rating to a “sell” rating in a report issued on Wednesday.

Separately, Zacks Investment Research upgraded shares of China Biologic Products from a “sell” rating to a “hold” rating in a research note on Wednesday, November 15th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and two have issued a buy rating to the company. The stock has an average rating of “Hold” and a consensus target price of $137.50.

China Biologic Products (CBPO) opened at $77.83 on Wednesday. China Biologic Products has a one year low of $72.21 and a one year high of $120.46. The firm has a market cap of $2,113.22, a price-to-earnings ratio of 17.05, a P/E/G ratio of 1.25 and a beta of 1.78.

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Jennison Associates LLC lifted its stake in shares of China Biologic Products by 0.8% during the 2nd quarter. Jennison Associates LLC now owns 5,775 shares of the biopharmaceutical company’s stock valued at $653,000 after buying an additional 44 shares in the last quarter. Geode Capital Management LLC lifted its stake in shares of China Biologic Products by 15.4% during the 1st quarter. Geode Capital Management LLC now owns 14,309 shares of the biopharmaceutical company’s stock valued at $1,432,000 after buying an additional 1,906 shares in the last quarter. Comgest Global Investors S.A.S. lifted its stake in shares of China Biologic Products by 135.0% during the 3rd quarter. Comgest Global Investors S.A.S. now owns 356,252 shares of the biopharmaceutical company’s stock valued at $32,872,000 after buying an additional 204,649 shares in the last quarter. Goldman Sachs Group Inc. lifted its stake in shares of China Biologic Products by 4.9% during the 2nd quarter. Goldman Sachs Group Inc. now owns 61,404 shares of the biopharmaceutical company’s stock valued at $6,945,000 after buying an additional 2,845 shares in the last quarter. Finally, Bank of New York Mellon Corp lifted its stake in shares of China Biologic Products by 30.1% during the 3rd quarter. Bank of New York Mellon Corp now owns 762,784 shares of the biopharmaceutical company’s stock valued at $70,380,000 after buying an additional 176,325 shares in the last quarter. Institutional investors own 65.13% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This piece was first posted by Watch List News and is the sole property of of Watch List News. If you are viewing this piece on another domain, it was illegally copied and reposted in violation of US & international copyright and trademark legislation. The correct version of this piece can be read at https://www.watchlistnews.com/china-biologic-products-cbpo-stock-rating-upgraded-by-bidaskclub/1773744.html.

About China Biologic Products

Receive News & Ratings for China Biologic Products Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China Biologic Products and related companies with MarketBeat.com's FREE daily email newsletter.